Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Bladder cancer (BCa) is a significant global health concern, necessitating improved diagnostic markers and novel therapeutic strategies.
• The renin-angiotensin system (RAS), comprising angiotensin type 1 (AT1R), type 2 (AT2R), and Mas receptors, plays a crucial role in tumorigenesis.
• Understanding RAS involvement offers potential avenues for BCa diagnosis and treatment.

Purpose of the Study:

• To investigate the role of RAS components in bladder cancer.
• To explore the therapeutic potential of targeting the renin-angiotensin system, specifically AT2R, in BCa.
• To evaluate AT2R as a potential diagnostic marker and therapeutic target for BCa.

Main Methods:

• Analysis of AT1R, AT2R, and Mas expression levels in BCa specimens.
• Viral vector-mediated overexpression of AT2R in BCa cells in vitro.
• Assessment of apoptosis and proliferation markers (caspase-3, caspase-8, p38, pErk).
• PCR Array analysis of apoptosis-related genes.
• In vivo studies using xenograft tumor models to evaluate AT2R's effect on tumor size, VEGF, and apoptosis.

Main Results:

• AT1R and Mas expression were upregulated, while AT2R was downregulated in BCa tissues.
• Overexpression of AT2R induced apoptosis and suppressed BCa cell proliferation in vitro.
• AT2R overexpression modulated key apoptosis-related genes and signaling pathways (e.g., increased caspase-3, caspase-8, p38; decreased pErk).
• In vivo, AT2R overexpression significantly reduced xenograft tumor size by downregulating VEGF and inducing apoptosis.

Conclusions:

• RAS components (AT1R, AT2R, Mas) show potential as diagnostic markers for BCa.
• AT2R demonstrates significant therapeutic promise as a novel target gene for BCa gene therapy.
• Targeting AT2R warrants further investigation for effective BCa treatment strategies.